# Why Compounded GLP-1 Drugs Became Popular

Canonical source: https://retacompare.com/research/why-compounded-glp1-popular-4

Compounded Peptides · 2026-01-02


    Compounded GLP-1 agonists exploded in popularity during 2023–2025 because of a convergence of forces: national shortages of branded semaglutide and tirzepatide, steep out-of-pocket pricing for uninsured patients, and rapid scaling by telehealth platforms that integrated prescribing, compounding, and direct-to-patient shipping into a single consumer experience. Consumers could often obtain a month of compounded semaglutide for $199–$299, compared to roughly $1,000+ for branded Wegovy. This price arbitrage, combined with online accessibility, attracted millions of users. That same accessibility drew scrutiny from regulators and from Eli Lilly and Novo Nordisk, setting the stage for the enforcement actions that have dominated 2026 news.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources